Repository logo
 
Publication

Antibodies Towards High-Density Lipoprotein Components in Patients with Psoriasis

2019Journal article Open access
Simple item page
dc.contributor.authorPaiva-Lopes, MJ
dc.contributor.authorBatuca, J
dc.contributor.authorGouveia, S
dc.contributor.authorAlves, M
dc.contributor.authorPapoila, AL
dc.contributor.authorDelgado Alves, J
dc.date.accessioned2024-05-15T15:20:39Z
dc.date.available2024-05-15T15:20:39Z
dc.date.issued2019
dc.description.abstractPsoriasis is a chronic inflammatory immune disorder associated with an increased risk of atherosclerosis. This increased risk is not fully understood. High-density lipoproteins (HDL) play an important role in the prevention of atherosclerosis and any factors that may hamper HDL function such as anti-HDL antibodies (aHDL) might be associated with an increased cardiovascular risk. We aimed to determine whether anti-HDL antibodies (aHDL) are present in patients with psoriasis. Sixty-seven patients with psoriasis were compared with a healthy control group. Epidemiologic and clinical data were recorded. IgG and IgM aHDL, IgG anti-apolipoprotein A-I (aApoA-I), anti-apolipoprotein E (aApoE), and anti-paraoxonase 1 (aPON1) antibodies, as well as VCAM-1, IL-6, and TNF-α were assessed by ELISA. Apolipoprotein A-I (ApoA-I) and Apolipoprotein E (ApoE) were measured by immunoturbidimetric immunoassay. Patients with psoriasis had higher titers of IgG aHDL (p < 0.001), IgG aApoA-I (p = 0.001) and aApoE antibodies (p < 0.001). IgG aHDL and aApoE titers were higher in patients with severe psoriasis (p = 0.010 and p = 0.018, respectively). Multiple regression analysis, considering all clinical and biological variables, showed that aApoE, IL-6, and aPON1 are the biological variables that best explain aHDL variability. This is the first report showing the presence of aHDL, aApoA-I, and aApoE antibodies in patients with psoriasis. These antibodies were associated with increased disease severity and may contribute to the pathogenesis of atherosclerosis in psoriasis. They may fulfill the clinical need for biomarkers of cardiovascular risk associated with psoriasis that would help to stratify patients for prevention and therapeutic approaches.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationArch Dermatol Res . 2020 Mar;312(2):93-102.pt_PT
dc.identifier.doi10.1007/s00403-019-01986-xpt_PT
dc.identifier.urihttp://hdl.handle.net/10400.17/4901
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherSpringerpt_PT
dc.subjectHSAC DERpt_PT
dc.subjectCHLC IMUpt_PT
dc.subjectCHLC CINVpt_PT
dc.subjectMalept_PT
dc.subjectFemalept_PT
dc.subjectHumanspt_PT
dc.subjectAdultpt_PT
dc.subjectAntibodies / blood*pt_PT
dc.subjectApolipoproteins / immunologypt_PT
dc.subjectBiomarkerspt_PT
dc.subjectCase-Control Studiespt_PT
dc.subjectMiddle Agedpt_PT
dc.subjectCholesterol, HDL / immunology*pt_PT
dc.subjectCytokines / geneticspt_PT
dc.subjectCytokines / metabolismpt_PT
dc.subjectImmunoglobulin Gpt_PT
dc.subjectPsoriasis / bloodpt_PT
dc.subjectPsoriasis / immunology*pt_PT
dc.titleAntibodies Towards High-Density Lipoprotein Components in Patients with Psoriasispt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage102pt_PT
oaire.citation.issue2pt_PT
oaire.citation.startPage93pt_PT
oaire.citation.titleArchives of Dermatological Researchpt_PT
oaire.citation.volume312pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Arch Dermat Res 2020 93.pdf
Size:
766.91 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

DER - Artigos
CINV - Artigos
IMU - Artigos